Featured
Status
Health Topics
Any CategoryDiseases
Neoplasms
-
- Histiocytic Disorders, Malignant 1
- Leukemia 35
- Lymphatic Vessel Tumors 2
- Lymphoma 41
- Neoplasms, Complex and Mixed 5
- Neoplasms, Connective and Soft Tissue 14
- Neoplasms, Germ Cell and Embryonal 28
- Neoplasms, Glandular and Epithelial 55
- Neoplasms, Nerve Tissue 23
- Neoplasms, Plasma Cell 7
- Neoplasms, Vascular Tissue 4
- Nevi and Melanomas 1
Search Clinical Trials
Recruiting
Trivalent CAR-T Cell in Acute B-Lineage Leukemia (TRICAR-ALL) (External Link)
The TRICAR-ALL T-cells were made in the laboratory by stimulating the patient's blood with growth factors to make the T cells grow. To get the CD19/CD20/CD22 antibody and 4-1BB to …
Baylor Role:
Lead Sponsor
Recruiting
EBV Specific T-Lymphocytes for Treatment of EBV-Positive Lymphoma (External Link)
The patient will donate blood in order to make C7R-EBV T cells. Depending on how long ago the cells were generated, they have been frozen. To get the C7R to …
Baylor Role:
Lead Sponsor
Recruiting
Neoadjuvant Folfirinox Combined With Pembrolizumab Followed by Surgery for Patients With Resectable Pancreatic Cancer (External Link)
This is a Phase II trial of NEOADJUVANT FOLFIRINOX CHEMOTHERAPY WITH PEMBROLIZUMAB followed by SURGERY and Adjuvant PEMBROLIZUMAB for Patients with LOCALIZED, RESECTABLE Adenocarcinoma of the pancreas. Investigators hypothesize that …
Baylor Role:
Lead Sponsor
Recruiting
HER2-specific Chimeric Antigen Receptor (CAR) T Cells for Children With Ependymoma (External Link)
PBTC-059 is a multicenter, Phase I and Surgical study of the treatment HER2-specific CAR T cells for patients with refractory or recurrent ependymoma. Phase I The primary objectives of the …
Baylor Role:
Collaborator
Withdrawn
CD19.CAR-multiVSTs for Patients With CD19+ B-ALL or NHL Undergoing Related Allogeneic HSCT (CARMA) (External Link)
First, a donor gave us blood to make CD19 chimeric receptor multivirus specific T cells in the laboratory. These cells are grown and frozen for the patient. To make these …
Baylor Role:
Lead Sponsor
Recruiting
Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors (External Link)
Approximately 15-24 subjects will participate in the treatment part of this study. Maximum of 180 mL of blood (not exceeding 3ml/kg/day) is collected from patients to grow the T cells …
Baylor Role:
Lead Sponsor
Recruiting
HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma (External Link)
Patients will first be asked to give blood to make the HER2 CAR T cells. These cells are grown and frozen for the patient. To get the HER2 antibody (and …
Baylor Role:
Lead Sponsor
Completed
Dendritic Cell Vaccination With Standard Postoperative Chemoradiation for the Treatment of Adult Glioblastoma (External Link)
This is a single arm (non-randomized) first-in-man pilot study to evaluate the safety and feasibility of delivering a dendritic cell vaccine in nine to twenty-four (n=9-24) adult patients diagnosed with …
Baylor Role:
Collaborator
Active, Not Recruiting
Multiple Myeloma Trial of Orally Administered Salmonella Based Survivin Vaccine (External Link)
The vaccine will be administered orally (by mouth) as a solution mixed with sodium bicarbonate. Approximately 10 minutes prior to receiving the vaccine, participants will take sodium bicarbonate pills to …
Baylor Role:
Lead Sponsor
Recruiting
Cell Therapy for High Risk T-Cell Malignancies Using CD7-Specific CAR Expressed On Autologous T Cells (External Link)
To make the T cells, the investigators will take the patient's blood and stimulate it with growth factors to make the T cells grow. To get the CD7 antibody and …
Baylor Role:
Lead Sponsor